1. A JC is an academic session in which we go through a scientific article over 60-90 min.
2. It takes place every Friday via our JC Discord channel โ€“ see calendar. 
3. Its purpose is to:

     - Understand, discuss and dissect relevant elements from the content.
     - Appraise whether they apply to or change our clinical practice.
     - Identify learning opportunities and potential research questions.

4. The selected article for the week is posted in our dedicated WhatsApp group.

5. We take interactive and pedagogic notes in a shared document, using visual aids, highlighting, underlining, arrows, and conceptual links to connect ideas and facilitate understanding.
6. For each session, we create RECAP key points and publish them on our website. 

7. In the following session, we briefly recall the previous JCโ€™s RECAP to reinforce learning through retrieval practice.

[2025 JAMA - SOFA-2 (Ranzani) [RCT].pdf]

Codified by MLHG

Glossary: 

Glossary: ๐Ÿง  = brain, ๐Ÿซ€ = heart, ๐Ÿซ = lungs, ๐Ÿซƒ๐Ÿฝ = abdomen = abdominal, ๐Ÿฉธ = blood = hematology, โ™พ๏ธ = kidneys = renal, โ—ธ = liver = hepatic, AUROC = area under the receiver operating characteristic, icuMM = ICU mortality


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, JAMA, WW โž– federated ๐Ÿค“ โž• 2M (>1k ICUs, 9 countries) โž• 2014 - 2023 โž– P I C O:
     - P: P: ICU pxs
     - ๐Ÿ…ธ: SOFA 1 variables ๐Ÿค“
     - ๐Ÿ…ฒ: NA
     - O: O: pOC = icuMM
3. EVIDENCE:
      a. SOFA-1 in 1996
      b. Changes โžฉ 30 years

      c. SOFA-1 does not capture DRUGS โž• DEVICES

      d. The new one should be GENERALIZABLE โžฉ high-, middle-, low- income countries. 

4. METHODS.

      a. Expert selection (60) โ–ถ๏ธŽ mDelphi โž• sr โž• internal + external validation

      b. 8 stages:

         i. 1-3 = identification (variables)โž• management (dysfunction)

         ii. Discussions โžฉ evidence gaps โž• clinical relevance

         iii. Scoreable construct โžฉ defined by:

            1. YES operational criteria

            2. NOT precise biological truth

            3. Priorities: SIMPLICITY + CLINICAL USABILITY + WIDESPREAD APPLICABILITY + - CONTENT VALIDITY. 

      - 6 domains: reliability โž• content โž• construct โž• criterion โž• predictive validity

      INTERV โž 

         - Expert input

         - internal + external validation

         - mDelphy - STAGE 1-5 

            - Expert input

      - Data-driven component (SOFA-2) - STAGE 6-8

         - geographical setting

         - resource setting

Validity

      - mDelphy โžฉ predictive validity w_AUROC curve (1st day of ICU)

5. RESULTS.

      1. Same 6 systems ๐Ÿง  โž– ๐Ÿซ โž– ๐Ÿซ€ โž– โ™พ๏ธ โž– โ—ธ โž– โ™พ๏ธ โ™พ๏ธ 
      2. w_new variables โž• thresholds
      3. SOFA-2 (AUROC 0.79) ๐Ÿ†š SOFA-1 (AUROC 0.77)      4. Sequential SOFA-2 data โžฉ ICU day 1 to 7 = same predictive validity      5. No data + No validity โžฉ ๐Ÿซƒ๐Ÿฝ + immune DYSF

โณ TIME MANAGEMENT.
01:33:02

Round: 10 00:17:92 Close
Round: 9 23:26:56 Wrap-up
Round: 8 05:47:34 Results
Round: 7 01:15:95 Comments
Round: 6 10:32:13 Interpretation
Round: 5 02:18:07 Reading + notes
Round: 4 27:21:39 Interpretation
Round: 3 16:48:65 Reading + notes
Round: 2 03:21:14 ART selection
Round: 1 01:53:22 Past JC

Friday, January 30, 2026 at 17:05:52 in BE

MASP, AAQC

โณ TIME MANAGEMENT.
01:42:18

Round: 10 00:41:09 Comments
Round: 9 17:17:59 Wrap-up
Round: 8 30:08:20 Identification (interpretation)
Round: 7 04:43:25 Identification (notes)
Round: 6 19:24:49 Definition
Round: 5 00:18:75 Titles + subtitles (4 min)
Round: 4 09:36:83 Interpretation (abstract)
Round: 3 04:52:36 Abstract (reading + notes)
Round: 2 06:28:64 ART selection
Round: 1 08:47:54 PAst JC

[2025 ICM - Cardiogenic shock diagnosis, phenotyping + mm (Moller) [r].pdf]

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (MASP)


Glossary: ABG w_lactate = arterial blood gas, AMI-CS = acute myocardial infarction with cardiogenic shock, BP = blood pressure, CAT LAB = catheterization laboratory, CRT = capillary refill time, CS = cardiogenic shock, DX = diagnosis, ID = identification, MCS = mechanical circulatory support, PAC = pulmonary artery catheter, TTO = treatment, UO = urine output, โˆ‘ = so, โžฐ = pressure, ๐Ÿ’จ = flow, ๐Ÿค“ = analysis, ๐Ÿ—ฃ = suggestion(s), โ˜… = recommendation(s).


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, ICM, DN โž– r โž• NA โž• NA

3. DEF. 

      a. โ†“๐Ÿ’จ critical โ†’ end-organ โ–ถ๏ธŽ function

      b. primary ๐Ÿซ€ failure โ–ถ๏ธŽ cause

      c. ๐Ÿซ€ cannot generate โ†’ SUFFICIENT OUTPUT โ–ถ๏ธŽ consequence 

      d. despite โ†’ adequate preload โ–ถ๏ธŽ condition
4. DX can be challenging โžฉ โˆ‘ we need HD measurements:

      a. โ†“ CI โ–ถ๏ธŽ โ‰ค2,2 โ€œtypicallyโ€

      b. โ†‘ PCWP โ–ถ๏ธŽ โ‰ฅ15 

      c. LVOT-VTI โ–ถ๏ธŽ gives SV
5. Identification
      a. EARLY recognition + therapy โ–ถ๏ธŽ cornerstone

      b. Lesson from STEMI โžฉ 1st โ€œgolden hourโ€ 

      c. ๐Ÿš‘ + ER deparment

         i. ID and TTO โžฉ CS โž• AMI-CS

         ii. Transfer directly to CAT LAB w_MCS (STEMI, NSTEMI, CS SCAI โ‰ฅclass B)

            1. Class B = โ†“BP โ†‘HR

            2. Class C = โ†“๐Ÿ’จ 

      d. ๐Ÿฅ โžฉ ECG 12 + tropoinin + lactate (10 min)

         i. Score ORBI โžฉ ๐Ÿ”—:  Orbi Risk Score

         ii. Score STOPSHOCK โžฉ ๐Ÿ”—: ๐Ÿคฏ [Stop Shock calculator ]

      e. SHOCK team โžฉ 30min evaluation

      f. Therapy โžฉ 60 min af_1st medical contact. 



















6. Special attention.

      a. โ™€ โž• old pxs โžฉ ATYPICAL symptoms

      b. Younger โžฉ โ†“ likelihood โžฉ โˆ‘โ†‘ likelihood to MISS CS DX. 

7. Af_DX โžฉ monitoring (BP, ECG, ABG w_lactate, UO)

      a. response

      b. progression

8. ECHO is mandatory โžฉ severity โž• etiology โž• phenotyping. 

9. PAC โžฉ IF a) unresponsive to INITIAL therapy, b) DX uncertainty (not supported by RCTs)

10. Clinical tools โžฉ mottling โž• CRT

11. Microcirculation

      a. may persist DESPITE NORMAL macrocirculation. 

      b. Method โžฉ sidestream dark field imaging. 

      c. DAMIS trial โ–ถ๏ธŽ sublingual microcirculation in mixed CS population โ–ถ๏ธŽ led to mm changes BUT did not correlate w_โ†‘OC. 

Friday, January 16, 2026 at 17:15:00 in BE

MASP, AAQC, PFLC, MNVC

January, 2026

February, 2026

Brief scope glossary

- ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ brief scope ๐ŸŸฐ Y, J, C โž– T โž• N โž• t โž– P I C O:

- year (Y), journal (J), country (C) โž– type of study (T) โž• patients/sample number (N) โž• time (t) โž– population (P), intervention (I), comparison (C), outcome (OC).

Glossary (most used)

๐Ÿซƒ๐Ÿฝ = abdomen = abdominal, ๐Ÿค“ = analysis, ๐Ÿ“ˆ = arrhythmia, ๐Ÿฉธ = blood = hematology, ๐Ÿง  = brain, โšก๏ธ = cardiac arrest, โญ•๏ธ = circulation, โ†“ = decrease, ๐—˜๐—ซ = exclusion, ๐Ÿ’จ = flow, ๐Ÿซ€ = heart, โ†—๏ธ = improve, ๐—œ๐—ก = inclusion, โ†‘ = increase, ๐ŸฅŠ = inflammation, ๐Ÿชฒ = infections, โ™พ๏ธ = kidneys = renal, โ—ธ = liver = hepatic, ๐Ÿซ = lungs, ๐Ÿ’ช๐Ÿฝ = muscle, โžฐ = pressure, ๐Ÿณ๏ธ = prevention, โ˜… = recommendation(s), โœ‹๐Ÿฝ = stop, ๐Ÿ—ฃ = suggestion(s), โ†˜๏ธ = worsen, CIpxs = critically ill patients, DX = diagnosis, h_LOS = Hospital length of stay, icu_LOS = ICU length of stay, inc_ = incident, MA = metaanalysis, mc = multicentric, MM = mortality, MM90 = mortality at 90 days, pOC = primary outcome(s), pxs = patients, RCT = randomized controlled trial, sOC = secondary outcome(s), sr = systematic review, SS = survival, w_ = with, wo_ = without, yo = years old. 

Complete glossary here

Friday, February 20, 2026 at 17:08:25 in BE

MASP, AAQC

2025 JAMA - The CDC No Longer Recommends C19 Shots During Pregnancy Now What (rubin) [mn].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (ABFL)


Glossary: CATE = conditional average treatment effect, cHTA = chronic hypertension, CKD = chronic kidney disease, f = CDC Advisory Committee for Immunization Practices, FRT-CI = Fisher Randomization Test for Confidence Intervals, NE = norepinephrine, RRT = renal replacement therapy, UP = urine output, VP_fd = vasopressor free days. 


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:

2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, ICM, FR โž– post-HOC โž• 776 โž• Mar 2010 - Dec 2011 โž– P I C O:
      - P: septic shock
      - ๐Ÿ…ธ: MAP 80-85
      - ๐Ÿ…ฒ: MAP 65-70
      - O: pOC = heterogeneity of treatment effect (HTE) | sOC = variable trajectories (MAP โž•             NE โž• lactate โž• mottling โž• UO)
3. EVIDENCE:
      a. 2014 NEJM - SEPSIS PAM (asfar)

         i. 2014, NEJM, FR โž– mc_prag_RCT โž• 776 โž• Mar 2010 - Dec 2011 โž– ๐Ÿ…ฟ๏ธ Septic                  shock, ๐Ÿ…ธ MAP 80-85 ๐Ÿ…ฒ MAP 65-70 ๐Ÿ…พ๏ธ pOC = MM28 | sOC = MM90 โž• AKI โž• sAKI                โž• nRRT 7dโž• RRT โž• VP_fd.

         ii. cHTA in high MAP group = โ†“ RRT โ–ถ๏ธŽ heterogeneity may exist ๐Ÿค”  
      b. SSC 2021 implemented โžฉ MAP 65
      c. Debate (higher BP better?) โžฉ chronic HTA โŒ„ CKD
      d. Personalized approach โžฉ has been repeatedely called out.
      e. FRT-CI helps TESTING heterogeneity โ–ถ๏ธŽ if substantial heterogeneity, CATE helps

4. METHODS.

      - INTERV โž  during 24h af_ VP start. 

          - Step 1. Randomization inference โž• FRT
          - Step 2. CATE โž• HTE variables <10%

      - Prespecified trajectories:

          - MAP. 80% of hourly MAP values (met ๐Ÿ†š unmet)
          - Lactate. โ‰ฅ ๐Ÿ†š < 2 d_1st 24h
          - UO: โ‰ฅ ๐Ÿ†š < 0.5 d_1st 24h
          - Mottling. yes ๐Ÿ†š no d_1st 24h

      - Unadjusted โžฉ then adjusted โ–ถ๏ธŽ logistic regression models โž• alluvial plots. 

      - Multi-mediation analyses w_4 randomization components: UO, lactate, mottling, NE โ†”               MAP goal responsiveness

5. RESULTS.

      1. Not meeting targets โžฉ โ†‘r MM
      2. MAP not reached โž• UO โ†“ (24h) โž• lactaet โ†‘ (24h) โž• mottling (24h) ๐ŸŸฐ โ†‘r MM
      3. The indirect effect was driven by NE exposure โž• mottling.
      4. See table 3

โณ TIME MANAGEMENT.
01:43:52

Round: 9 00:53:23 Comments
Round: 8 42:13:02 Interpretation all
Round: 7 08:52:45 Interpretation
Round: 6 02:51:21 I: read + notes
Round: 5 05:10:92 Structure
Round: 4 19:19:16 Reading + notes + interpretation
Round: 3 06:37:83 ART selection
Round: 2 00:35:50 Comments

Round: 1 17:19:20 Past JC

2025 ICM - Echocardiography guided management of AFib (Balik) [nr].pdf

Codified by YAPG


Glossary: ๐Ÿ“ˆ = arrhthmias, ๐Ÿ—ฃ = suggestion(s), ๐Ÿซ€ = heart, ๐Ÿซ€ Sร˜ = cardiogenic shock, ๐Ÿซ = lungs, AF = Atrial fibrilation, AL = afterload, antiCOA = anticoagulation, CCE = critical care echocardiography, DISF = disfunction, HD = hemodynamic, HR = heart rate, IVC = inferior vena cava, LVSF = left ventricular systolic function, LVF = Left ventricular filling, mm = management, MV = mechanical ventilated, NOAF = new onset atrial fibrillation, PH = pulmonary hypertension, RAP = right atrial pressure, r = risk, S&D = systolic and diastolic


1. EVIDENCE:

      a. AF โžฉ โ†‘ incidence
      b. In the ICU is MORE impactful โžฉ aggravated by illness severity
      c. NOAF โžฉ independent predictor MM
      d. ๐Ÿซ€ GL โ–ถ๏ธŽ MAJOR TRIALs:

          i. ambulatory pxs
          ii. different DEGREES ventricular S&D DYSF.
          iii. Variable dependences of LVF on ATRIAL SYSTOLE.

      e. Rate control โž• antiCOA โž• LIMITING any ๐Ÿซ€ depression in structural DIS scenarios                  (๐Ÿ—ฃ) ๐ŸŸฐ emphasis 

2. CCE:

      a. Diagnosis + monitoring. โžฉ in HD unstable pxs
      b. ID risk factors
      c. ID parameters โ†” ๐Ÿ“ˆ chronicity
      d. Guides therapy (sinus rhythm return) โžฉ rhythm control
      e. Decide: rhythm ๐Ÿ†š rate CONTROL
      f. Monitors โžฉ left atrial recovery post cardioversion
      g. Conflicting mm goals โžฉ **anticoagulation** (especially in significant r of bleeding)

3. LIMITED DATA โžฉ ACUTE benefits of rhythm OVER rate control โ–ถ๏ธŽ long-term seems to be the same. 

4. RCTs failed to CONSIDER the **degree** of โ€œpre-existing LV S&D DYSFโ€ (important for acutely decompensated pxs)
5. Rhythm control might be useful in certain populations โžฉ PHYSIOLOGICAL RATIONALE.
6. CCE โžฉ structure + function + risk stratification + mm guidance
7. LVSF โžฉ โ†‘ incidence ๐Ÿ“ˆ: atrial โž• ventricular. Prevalence: 

      a. 10-15% = AF w_moderate โ†“ LVEF
      b. 49% = AF w_severe โ†“ LVEF

8. NOAF โ†” LVEF <35% โžฉ non ๐Ÿซ€ CIpxs
9. RIght ventricule + PH

      a. RV Dilatation โ†” ๐Ÿ“ˆ
      b. AF prevalence 26-31% in all forms of PH
      c. ๐Ÿ“ˆ INDICATE (harginger) of clinical deterioration w_RV failure (context: PH)
      d. RA change โžฉ spherical remodelling โž• โ†‘ RAP โ–ถ๏ธŽ โ†” โ†‘ AF prevalence
      e. MV pxs w_Sร˜ โžฉ PH (SPAP โ‰ฅ51) after cardioversion โ†” MULTIPLE AF                                        RECURRENCES.
      f. ๐Ÿซ€ GL โ–ถ๏ธŽ use PEAK TRICUSPID PRESSURE GRADIENT wo_RAP (IVC diameter +                   respiratory variation) โžฉ although CVC is present (RAP is feasible)

10. Cor pulmonale

     a. May TRIGGER AF โžฉ โ†‘ HD instability
      b. Chronic PH โžฉ RV develops adaptaive wall hypertrophy โžฉ โ†‘ systolic pressure to                        counteract the AL.
      c. IF โ†ช๏ธŽ โ†“ RV contractility, โ†ช๏ธŽ RV failure โž• ๐Ÿซ€ Sร˜ [NOAF or โ†‘HR]

Friday, February 13, 2026 at 17:08:15 in BE

MASP, AAQC, PFLC, MNVC

โณ TIME MANAGEMENT.
01:39:50

Round: 11 01:09:41 Comments
Round: 10 40:00:54 Wrap-up
Round: 9 14:52:95 Interpretation
Round: 8 02:56:81 Reading + notes
Round: 7 08:52:19 Interpretation
Round: 6 04:12:06 REading + notes
Round: 5 11:53:50 Interpretation
Round: 4 03:10:69 Reading + notes
Round: 3 04:19:05 ART selection
Round: 2 00:55:75 Comments

Round: 1 07:27:80 Past JC

Friday, February 27, 2026 at 17:05:25 in BE

MASP, AAQC, PFLC, MNVC

โณ TIME MANAGEMENT.
01:29:16

Round: 10 01:59:19 Comments
Round: 5 15:02:89 Wrap-up
Round: 4 07:09:52 Interpretation
Round: 3 05:49:09 Reading + notes
Round: 2 03:07:86 ART selection
Round: 1 07:57:68 Past JC + 10min

2026 FPHYS - Real-time change in Dynamic CAR af_acupuncture at GB34 Yanglingquan, a self-controlled study (ZHANG) [R].pdf

Codified by YAPG


Glossary: ABP = arterial blood pressure, AdvEve = adverse events, af_ = after, BMI = body mass index, BP = blood pressure, CA = cerebral autoregulation, CBF = cerebral blood flow, dCA = dynamic cerebral autoregulation, DIS = disease, DM = diabetes mellitus, EtCOโ‚‚ = End-tidal carbon dioxide, GAD = generalized anxiety disorder, HR = heart rate, LF = low frequency, MCA = middle cerebral artery, MIN = minimum, NO DIFF = no difference, PV = phase value, SAH = subarachnoid hemorrhage, VRBPAC = FDAโ€™s Vaccines and Related Biological Products Advisory Committee, โ†‘THY = hyperthyroidism, ๐Ÿฅƒ = alcohol consumption, ๐Ÿšฌ = tabaquism, ๐Ÿง  = brain


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:

2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, FP, CH โž– sef-con_INT cross-over โž• 20 healthy โž• Sep โ€” Dec 2021 โž– P I C O:

      - P: Healthy volunteers
      - ๐Ÿ…ธ: 2 acupunture interventions (active)
      - ๐Ÿ…ฒ: Sham acupuncture
      - O:pOC = โ†โ†’phase levels af_GB34 | sOC = other CA parameters, MCA velocity, mean             BP, HR af_GB34.
3. EVIDENCE:
      a. CA โžฉ ๐Ÿง  maintains CBF despite ABP changes.
      b. dCA โžฉ transient response of CBF to rapid changes of BP โ–ถ๏ธŽ compromised:

         1. Stroke
         2. SAH

         3. Parkinson
         4. Panic disorder

         5. DM
         6. Depression

      c. 3. Few ๐Ÿ…ธ โ†‘ CA function.
      d. Acupuncture โžฉ popular in China โžฉ โœ”๏ธŽ clinical effects โž• โ†“ AdvEve
      e. GB34 = Yanglingquan โžฉ common function TTO in the clinic โ–ถ๏ธŽ used for:

         i. Stroke
         ii. Parkinson

      f. GB34 โžฉ โ†‘ CO2 reactivity in the ipsilateral MCA โžฉ โ†—๏ธ vasodilatory potential of ๐Ÿง  vasculature. 

4. METHODS.

      - ๐—˜๐—ซ โž  mental diseases + cerebrovascular DIS + TBI + HTA + ๐Ÿ“ˆ + DM + โ†‘THY + GAD +             depression + insomnia โž• ๐Ÿฅƒ โŒ„ ๐Ÿšฌ โž• poor cooperation, bone window.

      - INTERV โž  each par = 2 acupuncture ๐Ÿ…ธ

         - sterile, single-use needle
         - 20mm depth
         - Deqi sensation = needle reaction
         - 20s stimulation
         - 1 week interval โ†” acupuncture ๐Ÿ…ธ
         - Sequence of stimulus โžฉ active, sham.
         - dCA measurements โžฉ quiet room, controlled room, same technician.
         - Par AVOIDED โ–ถ๏ธŽ โ†‘ caloric meals (4h MIN), mod-vig exercise (12h MIN), coffee + ๐Ÿšฌ +                chocolate + ๐Ÿฅƒ (12h MIN).
         - 15-min rest.

      - TCD + photoplethysmography + EtCO2
      - dCA recording for 30 min โ–ถ๏ธŽ including 10min โ† acupuncture + 10min โ†’ needle removal.
      - TFA for CBFV + BP [page 3 detailed]

5. RESULTS.

     1. NO DIFF age โž• BMI
     2. NO changes ๐ŸŸฐ mean MCA + BP + EtCO2
     3. Left & right PV in LF band af_GB34 ๐ŸŸฐ ๐Ÿ…ธ โ†‘ than baseline.
     4. Other dCA af_GB34 ๐ŸŸฐ NO DIFF than baseline
     5. No real-time changes in dCA โžฉ in SHAM.
     6. Real-time changes in HR af_GB34. โžฉ โ†“ hrvCAR mentioned

March, 2026

Friday, March 27, 2026 at 17:05:30 in BE

LH, EQO, HIBN, MASP, AAQC

2026 AIC - Subphenotyping hypotension in early Sโ€ข, A physiology-guided therapeutic approach (sanchez) [ed].pdf

Codified by YAPG


GLOSSARY: โ˜… = recommendation(s), DAP = diastolic arterial pressure, DSI = diastolic shock index, HD = hemodynamics, Mech = mechanism, PP = pulse pressure, SAP = systolic arterial pressure, SV = stroke volume, artT = arterial tone, vT = vascular tone, venT = venous tone, ๐Ÿ’จ = perfusion, ๐Ÿซ€ DYSF = cardiac dysfunction


1. Continuationโ€ฆ
2. Subphenotypes (3)

a. โ†“VOL

i. Mech โ–ถ๏ธŽ ABSOLUTE โ†“VOL โ†” INF โž• preserved vT
ii. HD โ–ถ๏ธŽ

1. โ†“CO secondary to โ†“SV โžฉ โ†“PP โžฉ โ†“MAP
     a. PP = SAP - DAP
2. HR โ†‘ as a compensatory mech
3. DAP not โ†“ (if vT is preserved)

iii. TTO response โ–ถ๏ธŽ

1. When โ†“BP + โ†“ peripheral ๐Ÿ’จ โžฉ FR is needed, to โ†‘:

a. Stressed ๐Ÿฉธ volume
b. venous return
c. SV

b. โ†“ vT

i. Mech โ–ถ๏ธŽ

1. โ†“ artT + venT
2. Venous DILATION โžฉ relative โ†“VOL (redistribution: stressed โ†’ unstressed ๐ŸฉธVOL)

ii. HD โ–ถ๏ธŽ

1. Causes: โ†“ DAP + โ†‘ DSI (DSI = HR/DAP)
2. MAP is โ†“
3. CO is variable, depending: DEGREE of โ€œrelative โ†“ VOLโ€ โ†’ โ†“ vT
4. TTO response โ–ถ๏ธŽ

a. IF โ€œโ†“BP + peripheral โ†“๐Ÿ’จโ€ , NE is the TTO.

i.. alfa 1 - adrenergic
ii. โ†‘ artT โžฉ โ†‘DAP + MAP
iii. โ†‘ venT โžฉ moves ๐Ÿฉธ โ†’ stressed compartment.


c.๐Ÿซ€ DYSF

i. Mech โ–ถ๏ธŽ 

1. ๐Ÿซ€ depression โ†” Sโ€ข
2. Impaired CONTRACTILITY

ii. HD โ–ถ๏ธŽ

1. โ†“ SV
2. โ†“ PP
3. โ†“ MAP
4. DAP preserved
5. DIFFICULT to distinguish FROM โ†“VOL, so consider other factors:

a. context
b. previous ๐Ÿซ€ DIS
c. CV comorbidities
d. Clinical findings (๐Ÿซ edema)

6. ECHO is needed.

iii. TTO response โ–ถ๏ธŽ

1. Inotropic.


d. MIXED

โณ TIME MANAGEMENT
02:29:16

Round: 10 01:59:19 Comments
Round: 9 11:47:81  Wrap-up
Round: 8 12:03:26  Interpretation
Round: 7 03:32:76  Reading + notes
Round: 6 01:17:72  Comments
Round: 5 15:02:89  Wrap-up
Round: 4 07:09:52  Interpretation
Round: 3 05:49:09  Reading + notes
Round: 2 03:07:86  ART selection
Round: 1 07:57:68  Past JR + 10min

2026 AIC - Subphenotyping hypotension in early Sโ€ข, A physiology-guided therapeutic approach (sanchez) [ed].pdf

Codified by YAPG


Glossary: ACIP = CDC Advisory Committee for Immunization Practices, cHTA = chronic hypertension, CRT = capillary refill time, DAP = diastolic arterial presssure, DM = diabetes, DSI = diastolic shock index, DYSF = dysfunction, PP = pulse pressure, SAP = systolic arterial pressure, SI = shock index, VRBPAC = FDAโ€™s Vaccines and Related Biological Products Advisory Committee



1. โ†“ MAP โžฉ poor OC

2. Sโ€ข induced โ†“BP โ–ถ๏ธŽ

      a. โ†“ VOL โžฉ preload
      b. โ†“ vascular tone โžฉ afterload
      c. ๐Ÿซ€ DYSF โžฉ contractility
      d. Combination
3. Vasoplegia does NOT allow โ†‘ tissue perfusion

4. FLUID ACCUMULATION โžฉ worse OC
5. Concerns โ–ถ๏ธŽ need for early subphenotype-tailored therapeutic strategy.
6. Bedside variables to guide therapy:
      a. CRT. Does not define โ†“AP subphenotype alone, but CENTRAL to decision-making

         i. Prolonged = need for therapy. 

         ii. Normal = correction of โ†“โžฐ unnecessary UNLESS other signs of โ†“๐Ÿ’จ (altered mental                 status)

         iii. Its RESPONSE helps identify the underlying mech and the plan (continue โŒ„ change ). 
      b. PP.

         i. โ†“PP = โ†“SV
         ii. Arterial stiffness ๐Ÿšจ
         iii. Elderly + cHTA + DM โ–ถ๏ธŽ โ€œapparentlyโ€ normal (40-50 mmHg) ๐ŸŸฐ โ†“SV

      c. DAP.

         i. Except โ†“HR, โ†“ DAP (<45-50) ๐ŸŸฐ โ†“ vascular tone
      d. DSI

         i. HR / DAP.
         ii. โ†‘DSI (>3) โ–ถ๏ธŽ severe VASODILATION
         iii. More reliably than โ†“DAP
         iv. โ‰  SI โ–ถ๏ธŽ HR / SAP.

4. P-PHY subphenotypes

      a. โ†“VOL
      b. โ†“ vascular tone
      c. ๐Ÿซ€ DYSF


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:

2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2021, IJGO, UK โž– srMA โž• 2524, 59 IN โž• -Nov 11, 2020 โž– P I C O:

      - P: hALT pregnant
      - ๐Ÿ…ธ: preg hALT
      - ๐Ÿ…ฒ: preg non-hALT
      - O: pOC = hALT impact on LBW, SGA, SPTB | sOC = magnitude LBW

3. EVIDENCE.
4. METHODS.

      - ๐—œ๐—ก โž 
      - ๐—˜๐—ซ โž 
      - RANDOM โž 
      - INTERV โž 

5. RESULTS.
6. RATIONALE.7. LIMITATIONS.

Friday, March 13, 2026 at 16:31:12 in BE

MASP, AAQC, PFLC, MNVC

โณ TIME MANAGEMENT.
01:01:21

Round: 6 03:29:58 Comments
Round: 5 28:48:61 Interpretaion
Round: 4 09:56:25 Reading + notes
Round: 3 07:27:69 ART selection
Round: 2 01:37:51 Comments

Round: 1 10:01:43 Past JC

2026 BMJ - Careful ventilation in ARDS (Coudroy) [RCT].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (MASP)


Glossary: c-ARDS = COVID ARDS, d_ = duration, d_MV = duration of mechanical ventilation, EFF = efforts, hLOS = hospital length of stay, icuLOS = ICU length of stay, inspE = inspiratory effort, oDYS = organ dysfunction, Paw = airway pressure, Pinsp = inspiratory pressure, PSILI = patient self-induced lung injury, s&s = stress and strain, SOC = standard of care, s-t = short-term, VILI = ventilator- induced lung injury


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, BMJo, ARG + CA + CL + FR + IT + ES + NL + US โž– invest-led_mc_ol_RCT (basket) โž• 740 โž• 6y (Nov 2020 - Jul 2026) โž– P I C O:

๐Ÿ…ฟ: ARDS & c-ARDS

๐Ÿ…ธ: 2 ventilatory strategies

๐Ÿ…ฒ: SOC

๐Ÿ…พ: pOC = MM60 | sOC = d_MV โž• d_icuLOS & hLOS


3. EVIDENCE

a. 10% of ICU admissions is ARDS
b. 23% of ventilated pxs is ARDS
c. s-t MM is 40% ๐Ÿ˜ณ
d. Causes: ๐Ÿซ , Sโ€ข, TRAUMA, pancreatitis
e. ๐Ÿซ โžฉ inflamed + edematosos โžฉ โ†“ volume + compliance โ–ถ๏ธŽ difficult ventilation
f. MV can cause VILI โžฉ adverse HD consequences
g. c-ARD โžฉ severe form โž• complex physiology โž• varies widely โž• โ˜… uncertain. โ–ถ๏ธŽ โ†‘ โ†‘ โ†‘ MM
h. NO TTO for the alveolar-capillary leak
i. YES supportive TTO โžฉ MV โž• NMB โž• prone
j. RCT โ–ถ๏ธŽ GL โ–ถ๏ธŽ โ†“r VILI w_: โ†“Vt โž• โ†“Paw โžฉ โ†“ stress & strain
k. Other STUDIES โ–ถ๏ธŽ contemporary strategies are NOT SUFFICIENTLY protective.
l. PEEP is not used properly:

i. โ†“ atelectrauma ๐ŸŸฐ opening + closing of alveoli
ii. โ†‘ recruitment ๐ŸŸฐ โ†‘ aerated ๐Ÿซ โ†’โˆ‘ โ†“ s&s

m. โ†‘ โ†‘ โ†‘ PEEP โžฉ โ†‘MM [when alveoli NOT recruitable]
n. Authos described a technique to measure ALVEOLAR RECRUITABILITY
o. Spontaneous breathing & assisted MV โžฉ PSILI
p. ๐Ÿซ DRIVE โ–ถ๏ธŽ โŠ• ๐Ÿซ โž• systemic INFLAMMATION โž• unmyelinated afferent fibres โž• slow & rapid adaptive receptors (nociceptive stimuli + blunted โŠ– response).

i. โ†‘ in ARDS pxs
ii. โ†‘ โ†‘ in c-ARDS pxs
iii. โ†” โ†‘d_MV
iv. โ†‘ MM

q. ๐Ÿซ inspE โ–ถ๏ธŽ โ†‘ distending (transpulmonary) pressure โ–ถ๏ธŽ ๐Ÿซ ๐ŸฅŠ โž• oDYS
r.  HYPOTHESIS: ๐Ÿซ injury โ†“ โž• SS โ†‘

i. individualizing PEEP
ii. โ†“ MAX Pinsp
iii. โ†“ magnitude spontaneous breathing EFF

s. PEEP

i. Set wo_knowledge of the potential of recruit โ€“ only set on O2
ii. โ† RCTs compared 2 levels of PEEP โžฉ BUT, none looked at ๐Ÿซ recruitment.
iii. Noncrecuitable ๐ŸŸฐ r_overdistention
iv. Recruitable ๐ŸŸฐ repetitive ๐Ÿซ open-close
v. โ˜… โžฉ โ†‘ PEEP but individual โ˜… vary.

vi. List

4.  SOURCE: https://pubmed.ncbi.nlm.nih.gov/41730551/ 

โณ TIME MANAGEMENT.
02:29:16

Round: 10 01:59:19 Comments
Round: 9 11:47:81 Wrap-up
Round: 8 12:03:26 Interpretation
Round: 7 03:32:76 Reading + notes
Round: 6 01:17:72 Comments
Round: 5 15:02:89 Wrap-up
Round: 4 07:09:52 Interpretation
Round: 3 05:49:09 Reading + notes
Round: 2 03:07:86 ART selection
Round: 1 07:57:68 Past JR + 10min

Friday, April 24, 2026 at 18:35:53 in BE

TGA, MASP, AAQC, HIBN

2026 AIC - Subphenotyping hypotension in early Sโ€ข, A physiology-guided therapeutic approach (sanchez) [ed].pdf

Codified by YAPG


Glossary: d_ = during, FR = fluiid responsiveness, hLOS = hospital lenght of stay, iFR = fluid responsiveness indices, ivT-R = indices of vascular tone responsiveness, rโŒ„i = responsiveness or intolerance, SUPP = support, VA = vasoactives, ยตCIR = microcirculatory, ๐Ÿซ€ = heart, ๐Ÿซ = lungs


1. Mixed subphenotypes:

     a. SEPSIS โžฉ combinations:

         i. โ†“VOL + โ†“vT

              1. โ†“ PP + โ†“ DAP

              2. TTO โžฉ fluids + NE 

              3. Delaying NE is RISKY โ–ถ๏ธŽ 

                    a. fluids may worsen VASODILATION. 

                    b. early NE movilizes VENOUS BLOOD 

        ii. ๐Ÿซ€DYSF + โ†“vT โŒ„ ๐Ÿซ€DYSF + โ†“VOL. Before DOBUTAMINE:

             1. Dx ๐Ÿซ€ DYSF should be WELL STABLISHED.

             2. ANY โ†“VOL โž• โ†“vT SHOULD BE corrected. If Dobuta:

                 a. Poorly tolerated. 

                 b. โ†˜๏ธ โ†“vT

        iii. MIXED 3 mechs โžฉ varying proportions (emerging + receding + combining to โ‰  degrees)


2. Beyond early subphenotyping
      a. Subphenotying is not all.
      b. Additional considerations:
         i. MAP targets

         ii. FR rโŒ„i

         iii. VP rโŒ„i

         iv. Evolving ยตCIR behavior

         v. need ongoing ADJUSTMENT

      c. Advanced clinical TOOL 

i. ScvO2
ii. โˆ†CO2
iii. iFR
iv. ivT-R
v. VExUS

d. More invasive HD monitoring โžฉ in COMPLEX CASES

i. unresponsive to initial therapy
ii. fluid benefit-risk assessment (e.g. ARDS)

e. Integration of all โžฉ implementation of a PESRONALIZED, PX TAILORED APPROACH. 


3. CLIINICAL IMPLICATIONS


a. Subphenotyping is a KEY STEP โ†’ precision resuscitation.
b. When combined w_CLINICAL CONTEXT โž• SIMPLE BEDSIDE MARKERS ๐ŸŸฐ ID mechs โ–ถ๏ธŽ administer fluids, VP, INO, โŒ„ combination.
c. Recent evidence โ–ถ๏ธŽ ANDROMEDA-SHOCK-2

i. โ†‘ OC
ii. ๐Ÿ…ธ CRT-PHR = personalized hemodynamic resuscitation protocol
targeting capillary refill time
iii. pOC = combined: MM โž• d_vital SUPP (VA, MV, RRT) โž• hLOS 28d
iv. ๐Ÿ…ธ (better) ๐Ÿ†š usual care

     

โณ TIME MANAGEMENT.
01:48:07

Round: 7 01:11:38  Comments
Round: 6 21:12:56  Wrap-up
Round: 5 41:46:90  Interpretation
Round: 4 03:56:96  Reading + notes
Round: 3 00:14:59  Same topic
Round: 2 37:30:69  Continue wrap-up
Round: 1 02:13:96  Past JC

Friday, April 10, 2026 at 18:15:06 in BE

SR, HBN, EQO, MASP, AAQC

April, 2026

2026 ICM - Temporary mechanical support in fulminant myocarditis, prognostic factors + clinical implications, FULLMOON study (Schmidt) [R].pdf

Codified by YAPG


Glossary: AdvOC = adverse outcomes, EMB = endomyocardial biopsy, FM = fulminant myocarditis, HTx = heart transplantation, LVAD = left-ventricular assist device, t-MCS = temporary mechanical circulatory support, wOC = worse outcome.


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, ICM, 15C โž– cohort FULMOON (int_mc_retro_โ€registryโ€) โž• 295/419 pxs (36 centers)โž• Jan 2008 - Jan 2020 (12y) โž– P I C O:

๐Ÿ…ฟ: FM + V-A ECMO ยฑ impella

๐Ÿ…ธ: NA

๐Ÿ…ฒ: NA

๐Ÿ…พ: pOC = MM 1y โŒ„ HTx โŒ„ LVAD


3. EVIDENCE

a. FULLMOON โ–ถ๏ธŽ EHJ 2023, Huang et al. โžฉ DX made by:

i. histologically = 50%
ii. autopsy = 28%
iii. MRI = 23%

b. t-MCS โ–ถ๏ธŽ โ†‘ used in FM โžฉ OC + rf are POORLY DEFINED.


4. METHODS.

  • Multivariate Cox regression โžฉ predictors of AdvOC
  • Propensity score-weighted ๐Ÿค“ โžฉ EMB:
    • early โ‰ค2d
    • delayed >2d
    • none

5. RESULTS.

a. Age 39y (55% โ™€)

b. Confirmed 69% (histological + MRI)

c. Causes:

i. HTA
ii.๐Ÿฉธ hh
iii. SSร˜

d. UNIVARIATE

i. diastolic HTA (RR 2,7. p=0.0001) AUROC 0,58. p=0.003
ii. severe bleeding > 1000mL (RR 11. p=0.0001) AUROC 0,56. p=0.03
iii. CRT > 3,5s (RR 14,2. p=0.0001) AUROC 0,72. p=0.001

e. MULTIVARIATE

i. severe bleeding > 1000mL
ii. CRT > 3,5s

f. Better RR with CRT. 

Friday, May 29, 2026 at 18:14:30 in BE

TGA, KYEC, MLHG, HIBN, AAQC,

โณ TIME MANAGEMENT.
01:25:51

Round: 6 02:13:52 Comments
Round: 5 25:07:88 RECAP
Round: 4 36:11:17 Interpretation
Round: 3 09:30:58 Reading + notes
Round: 2 05:32:34 JR selection
Round: 1 07:16:23 Past JR

Friday, May 29, 2026 at 18:14:30 in BE

TGA, KYEC, MLHG, HIBN, AAQC,

6. RATIONALE

a. Pregnancy is related to microcirculation derangements.

b. Sublingual alterations shown.
c. Strong prolonged CRT โ†” sublingual ยตCIR โžฉ SSร˜
d. Current TTO might MODULATE this network.


7. SOURCE: Monares Zepeda et al. Critical Care https://doi.org/10.1186/s13054-025-05404-9 (2025) 29:231

2026 BMJ - CAVIARDS, careful ventilation in ARDS (Coudroy) [RCT].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (MASP)


Glossary: c-ARDS = COVID ARDS, d_ = duration, d_MV = duration of mechanical ventilation, EFF = efforts, hLOS = hospital length of stay, hPEEP = high PEEP, icuLOS = ICU length of stay, inspE = inspiratory effort, NRD = neural respiratory drive โœฉ, oDYS = organ dysfunction, Paw = airway pressure, Pinsp = inspiratory pressure, Pplat = plateau pressure, PSILI = patient self-induced lung injury, Ptp = transpulmonary pressure, REC = recruitability, rf = risk factors, s&s = stress and strain, SOC = standard of care, s-t = short-term, VILI = ventilator- induced lung injury


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, BMJo, ARG + CA + CL + FR + IT + ES + NL + US โž– invest-led_mc_ol_RCT (basket) โž• 740 โž• 6y (Nov 2020 - Jul 2026) โž– P I C O:

๐Ÿ…ฟ: ARDS & c-ARDS

๐Ÿ…ธ: 2 ventilatory strategies

๐Ÿ…ฒ: SOC

๐Ÿ…พ: pOC = MM60 | sOC = d_MV โž• d_icuLOS & hLOS


3. EVIDENCE

a. 2 criteria to set PEEP (for this study):

i. R/I ratio โ†’ for predicting alv_REC
ii. ยซOne-breath decremental PEEPยป โ†’ distinguishes: recruitable ๐Ÿ†š non-recruitable
iii. <5min
iv. It should:

1. avoid harm of hPEEP (when not recruitable)
2. allow hPEEP only when recruitable

v. This happens when R/I >0.5. 

b. Airway closure

i. Complete closure is >5 cmH2O โžฉ 30-40% โžฉ defines the minimum PEEP.
ii. Humans and animal might have the same damage.
iii. Pressure-time curve helps detecting it. (low-flow inflation)
iv. PRO: (due to better understanding of the alveoli than Paw)

1. avoiding repeated opening-closure.
2. corrects assessment of plateau + driving P

v. Necessary step BEFORE measuring recruitability.

c. Maximal inp distending P

i. Assessed by Pplat โ†’ to titrate Vt
ii. GL โ–ถ๏ธŽ limits Vt + Paw + PEEP

d. ๐Ÿซ drive โž• spontaneous breathing effort

i. D_SPONTANEOUS breathing: โ†‘ resp drive โž• large resp efforts ๐ŸŸฐ PSILI + diaphragm DYS
ii. 2018 ICM, Brochardโ€ฆ 2020 BLUE, Rittayamai โžฉ P0.1

1. simple tool on ventilator
2. Reflects: NRD โžฉ guide level os assistance + sedation.
3. โˆ‘ โ†“r: excessive Ptp โžฉ โ†“ rPSILI

iii. MECHS assessment CONTROLS the 3rf (underlined above)
iv. MECHS:

1. alveoli recruitability
2. R/I ratio
3. total PEEP
4. Pplat
5. โˆ†P
6. resp system COMPLIANCE

7. P0.1

e. HYPOTHESIS. individualizing ventilator setting based on RESP MECHS โ†’ more effective โœ”๏ธŽ

โณ TIME MANAGEMENT.
01:22:05

Round: 7 02:33:44 Comments
Round: 6 29:57:18 RECAP
Round: 5 11:17:01 Interpretation
Round: 4 01:13:60 Reading + notes
Round: 3 23:06:18 Evidence (2nd part)
Round: 2 13:21:09 JC continuation
Round: 1 00:37:39 PAst JC

Friday, May 8, 2026 at 18:30:59 in BE

SC, TGA, RCH, BAR, DEPZ, YAPG, HIBN, AAQC,

May, 2026

August, 2026

2025 JAMA - BICARICU-2, Sodium Bicarbonate for Severe Metabolic Acidemia + AKI (jung) [RCT].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (MASP)


Glossary:
๐Ÿง  = brain
๐Ÿซ = lungs
๐Ÿซ€ = heart
๐Ÿซƒ๐Ÿฝ = abdomen = abdominal

โ—ธ = liver = hepatic
โ™พ๏ธ = kidneys = renal
๐Ÿฉธ= blood = hematology
๐Ÿชฒ = infections
๐Ÿ’จ = flow
โžฐ = pressure
๐Ÿค“ = analysis;
โšก๏ธ = cardiac arrest;
๐Ÿ“ˆ = arrhythmia;
๐Ÿ—ฃ = suggestion(s)


โ˜… = recommendation(s)


AF = atrial fibrillation;


VRBPAC = FDAโ€™s Vaccines and Related Bio-
logical Products Advisory Committee


ACIP = CDC Advisory Committee for Immunization Practices


sev = severe


MeAc = metabolic acidemia


OS = organ suport


VP = vasopressors


iMV = invasive mechanical ventilation


FLU = fluid balance


MAKE = major adverse kidney events


NO DIFF = no difference


imp_ = impairment


DYS = dysfunction


OF = organ failure


Sโ€ข = sepsis



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, JAMA, FR โž– ol_ii_mc_RCT โž• 640 โ†’ 627 (313 ๐Ÿ†š 314) [43 ICUs] โž• -Oct 2019 - Dec 2023 | ฦ’-up 90d (last 2024) โž– P I C O:

๐Ÿ…ฟ: Adults (sev_MeAc โž• sev&mod_AKI)

๐Ÿ…ธ: HCO3

๐Ÿ…ฒ: no HCO3

๐Ÿ…พ: 

  • pOC = MM90
  • sOC = MM28 + MM180 โž• OS therapy โž• VP โž• iMV โž• โ€œicu_ & h_โ€ LOS โž• icu_INF โž• FLU โž• SOFA 7 โž• MAKE 90 (they are 18 sOC)

3. EVIDENCE

a. Effects of HCO3 in ๐Ÿ…ฟ are โ“ 

       b. pH โ‰ค 7,2:

i. = ๐Ÿซ€
          1. imp_contractility
          2. ๐Ÿ“ˆ
ii. ๐Ÿฉธ: systemic vasodilation
iii. โ™พ๏ธ: imp_ blood ๐Ÿ’จ 
iv. ๐Ÿง : edema
v. ๐Ÿซ: diaphragmatic DYS

c. CAUSES (MeAc), d_AKI:

              i.       โ†‘Cl acidosis
              ii.      โ†‘ Lac
              iii.     โ†‘ endogenous anion

       d. BICARICU-1

              i.      โœ”๏ธŽ Na HCO3 4,2% ๐Ÿ…ธ ๐Ÿ†š โœ–๏ธŽ Na HCO3 ๐Ÿ…ฒ
              ii.      ๐Ÿ…ฟ sev_MeAc
              iii.     pOC = MM28 โŒ„ OF 7d โŒ„ both โžฉ ๐—ก๐—ข ๐——๐—œ๐—™๐—™

              iv.     Preplanned ๐Ÿค“

        e. OBSERVATIONAL

              i.      Benefits ๐Ÿ…ธ:

                    1. sev_MeAc + sev_AKI โž• very sev_MeAc (pH < 7,15) โ–ถ๏ธŽ ICM 2018 โž• CCM 2019                                                                   2. >60yo โž• Sโ€ข โž• mod_Ac โ–ถ๏ธŽ Front Pharmacol.2023

         f. TARGET TRIAL EMULATION

               i.       >6k pxs
               ii.       HCO3 โ†” โ†“ MM30
         g. STUDIES

               i.        AKIKI (NEJM 2016)
               ii.       AKIKI-2 (LANCET 2021)

               iii.      CRICS TRIGGERSEP (NEJM 2018)

               iv.      STARRT-AKI (NEJM 2020)

4. METHODS.

  • ๐—œ๐—ก โž 
  • ๐—˜๐—ซ โž :
  • RANDOM โž  1:1
  • INTERV โž 
  •       - Target โ†’ pH โ‰ฅ 7,30
  • DEFINITIONS โž 
  • sev_MeAc = pH โ‰ค 7,20

5. RESULTS.

a. 67yo โž– 59% โ™‚๏ธŽ

b. 62% ๐Ÿ…ธ

c. MM90 (p = 0.91)

i.      62,1% โ†’ ๐Ÿ…ธ
ii.     61,7% โ†’ ๐Ÿ…ฒ

d. acMM 28 & 180 โ†’ NO DIFF

e. RRT (-23.1 to -7.8)

i.      35% โ†’ ๐Ÿ…ธ
ii.     50% โ†’ ๐Ÿ…ฒ

f. Others โ†’ NO DIFF

6. RATIONALE.

7. LIMITATIONS.

8. SOURCE: 

Friday, June 26, 2026 at 18:49:35

EQO, OWGG, BAR, SLDC, HIBN, AAQC,

โณ TIME MANAGEMENT.
01:39:58

Round: 8 00:41:90 Comments
Round: 7 30:02:31 Intepretation + RECAP
Round: 6 03:10:67 Introduction (reading + notes)
Round: 5 37:26:06 Interpretation + RECAP
Round: 4 03:57:56 Reading + notes
Round: 3 10:39:32 ART selection
Round: 2 00:53:33 Comments
Round: 1 13:07:48 Last JC

โณ TIME MANAGEMENT.
01:49:10

Round: 8  00:29:27  Comments
Round: 7  26:27:83  Article
Round: 6  43:03:47  RECAP
Round: 5  13:15:33  Interpretation
Round: 4  03:41:82  Reading + notes
Round: 3  13:02:43  ART selection
Round: 2  00:36:18  CommentsRound: 1  08:33:92  Past JC

6. RATIONALE.

a. The benefit was seen since 2y
b. NNT 1 = 35 (95% CI, 24 5o 53)
c. PROGRESS pxs who participated = 660

i. perindopril ยฑ indapamide ๐Ÿ†š placebo
ii. 4y
iii. โ†“BP 11/4 โ†” โ†“r Sโ€  (49%)

d. ol_T:

i. ๐Ÿ…ธ: more intensive ๐Ÿ†š ๐Ÿ…ฒ: less intensive
ii. ยฎ: **โ†“**r_rec_IH = ๐Ÿ…ธ โžฉ in pxs w_prev_โ€iSโ€  โŒ„ IHโ€

e. Cohort + mendelian RAN

i. BP โ†” IH


7. SOURCE: Trident Research Group, Anderson CS, Chow CK, et al. Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage. N Engl J Med. 2026;394(16):1571-1582. doi:10.1056/NEJMoa2515043

5. RESULTS.

a. 58yo

b. Recurrent Sโ€  (p=0.02) โ†’

i. 4,6% โ†’ ๐Ÿ…ธ
ii. 7,4% โ†’ ๐Ÿ…ฒ

c. SBP (mmHg) (p<0.001)

i. 127 โ†’ ๐Ÿ…ธ
ii. 138 โ†’ ๐Ÿ…ฒ

d. MACE (p=0.04)

i. 6.6% โ†’ ๐Ÿ…ธ
ii. 9.8% โ†’ ๐Ÿ…ฒ

e. ร†

i. 23,2% โ†’ ๐Ÿ…ธ
ii. 26% โ†’ ๐Ÿ…ฒ

f. Discontinuation

i. 13,6% โ†’ ๐Ÿ…ธ
ii. 6% โ†’ ๐Ÿ…ฒ
iii. most common ร† โ†’ โ†‘ crea โ‰ฅ20%

g. MM ๐Ÿซ€ (p=0.21)

i. 2% โ†’ ๐Ÿ…ธ
ii. 3% โ†’ ๐Ÿ…ฒ

h. pOC incidence:

2026 NEJM - TRIDENT, three Low-Dose Antihypertensive Agents in a Single Pill af_icHH (anderson) [R].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (TGA)


Glossary: โ›”๏ธ = contraindication, MI = myocardial infarction, MACE = major cardiovascular events, ol = open label, RAN = randomization studies, rec = recurrent, SBP = systolic blood pressure, Sโ€  = stroke, T = trials, IH = intracerebral hemorrhage, โ™พ๏ธ = kidneys = renal, โ—ธ = liver = hepatic, ๐Ÿง ache = headache


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, NEJM, 12C (AU, BR, GE, MY, NL, NG, SG, LK, CH, TW, GB, VN) โž– mn_db_RCT โž• 1670pxs (833 ๐Ÿ†š 837) โž• Sep 2017 - Nov 2024 | f-up 2,5y โž– P I C O:

- ๐Ÿ…ฟ: pxs w_history spontaneous icHH (inpxs or outpxs)

- ๐Ÿ…ธ: once-daily pill w_3 antiHTA agents โž• usual TTO

- ๐Ÿ…ฒ: placebo โž• usual TTO only

- ๐Ÿ…พ: pOC = 1st rec_Sโ€  | sOC = BP control + MACE + MM ๐Ÿซ€ causes + safety


3. EVIDENCE

a. โ†“ BP โžฉ only proven TTO for Sโ€ 
b. Does a pill (combination of 3 antiHTA) โ†“BP โž• โ†“r recurrent Sโ€  โ“


4. METHODS.

  • ๐—œ๐—ก โž  SBP 130-160 โž• stable condition โž• no โ›”๏ธ to the pill content
  • ๐—˜๐—ซ โž  ACE โŠ– not replaceable โž• abnormal tests: โ™พ๏ธ + โ—ธ โŒ„ both.
  • RANDOM โž  1:1
  • INTERV โž 
    • 2-week active run-in phase โ†’ pill administration to ALL
    • PILL = telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg.
    • 72 months of total f-up
  • DEFINITIONS โž 
    • BP control = SBP < 130 at 6m af_RAN
    • MACE = nonfatal myocardial infarction ยฑ nonfatal stroke ยฑ death
      from cardiovascular causes; whichever occurred 1st.
    • Other OC = recurrent icHH + iSโ€  + Sโ€  unknown type + nonfatal MI + MM_Sโ€  + MM_anyC + other measures of BP control.
    • Adherence = missing doses (1 in 1-7days in the pre-week) + pill counts
    • Safety = serious ร† + ร† of special interest (โ†“AP, syncope, ๐Ÿง ache, โ†“Na, โ†‘K, falls, AKI)

Friday, June 12, 2026 at 18:02:19 in BE

TGA, SARG, KSQV, KYEC, DEPZ, HIBN, AAQC,

Friday, June 26, 2026 at 18:49:35

EQO, OWGG, BAR, SLDC, HIBN, AAQC,



2025 JAMA - BICARICU-2, Sodium Bicarbonate for Severe Metabolic Acidemia + AKI (jung) [RCT].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (MASP)


Glossary: ADM = admission, DYS = dysfunction, FLU = fluid balance, iMV = invasive mechanical ventilation, imp_ = impairment, MAKE = major adverse kidney events, MeAc = metabolic acidemia, NO DIFF = no difference, OF = organ failure, OS = organ support, Sโ€ข = sepsis, sc = single center, sev = severe, SOFA = Sequential [Sepsis-related] Organ Failure Assessment, VP = vasopressors.


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, JAMA, FR ๐Ÿ‡ซ๐Ÿ‡ท โž– ol_ii_mc_RCT โž• 640 โ†’ 627 (313 ๐Ÿ†š 314) [43 ICUs] โž• -Oct 2019 - Dec 2023 | ฦ’-up 90d (last 2024) โž– P I C O:

- ๐Ÿ…ฟ: Adults (sev_MeAc โž• sev&mod_AKI)

- ๐Ÿ…ธ: HCO3

- ๐Ÿ…ฒ: no HCO3

- ๐Ÿ…พ: 

             -     pOC = MM90

             -     sOC = MM28 + MM180 โž• OS therapy โž• VP โž• iMV โž• โ€œicu_ & h_โ€ LOS โž• icu_INF โž• FLU โž• SOFA 7 โž• MAKE 90 (they are 18 sOC)


3. EVIDENCE

a. Effects of HCO3 in ๐Ÿ…ฟ are โ“
b. pH โ‰ค 7,2:

           i.    ๐Ÿซ€

                   1.     imp_contractility
                   2.     ๐Ÿ“ˆ

           ii.      ๐Ÿฉธ: systemic vasodilation

           iii.     โ™พ๏ธ: imp_ blood ๐Ÿ’จ

           iv.     ๐Ÿง : edema

           v.      ๐Ÿซ: diaphragmatic DYS 
            

4. CAUSES (MeAc), d_AKI:

       a. โ†‘Cl acidosis

       b. โ†‘ Lac

       c. โ†‘ endogenous anion


5. BICARICU-1

       a. โœ”๏ธŽ Na HCO3 4,2% ๐Ÿ…ธ ๐Ÿ†š โœ–๏ธŽ Na HCO3 ๐Ÿ…ฒ

       b.  ๐Ÿ…ฟ sev_MeAc

       c.  pOC = MM28 โŒ„ OF 7d โŒ„ both โžฉ ๐—ก๐—ข ๐——๐—œ๐—™๐—™
       d.  Preplanned ๐Ÿค“

             i.     sev&mod_AKI, MM28:  

                    1. 63% ๐Ÿ…ฒ               

                    2. 46% ๐Ÿ…ธ

             ii.    RRT:
                    1. 73% โ†’ ๐Ÿ…ฒ
                    2. 51% โ†’ ๐Ÿ…ธ

       e. โ€œtemporizing measure to delay KRT initiationโ€

โณ TIME MANAGEMENT.
01:39:58

Round: 10 01:59:19 Comments
Round: 7 30:02:31 Interpretation + RECAP
Round: 6 03:10:67 Introduction (reading + notes)
Round: 5 37:26:06 Interpretation + RECAP
Round: 4 03:57:56 Reading + notes
Round: 3 10:39:32 ART selection
Round: 2 00:53:33 Comments
Round: 1 13:07:48 Last JC


6. OBSERVATIONAL

a. Benefits ๐Ÿ…ธ:

           i.    sev_MeAc + sev_AKI โž• very sev_MeAc (pH < 7,15) โ–ถ๏ธŽ ICM 2018 โž• CCM 2019

           ii.   60yo โž• Sโ€ข โž• mod_Ac โ–ถ๏ธŽ Front Pharmacol.2023

        

            

7. TARGET TRIAL EMULATION

       a. 6k pxs

       b. HCO3 โ†” โ†“ MM30


8. STUDIES

       a. AKIKI (NEJM 2016)

       b.  AKIKI-2 (LANCET 2021)

       c.  CRICS TRIGGERSEP (NEJM 2018)
       d.  STARRT-AKI (NEJM 2020)


9. METHODS.

  • ๐—œ๐—ก โž 

               -    SOFA > 4 โŒ„ LAC โ‰ฅ2 (48h af_ADM), โž•

               -    criteria (6h prev):

  • ๐—˜๐—ซ โž 
  • RANDOM โž  1:1
  • INTERV โž 

                -    Target โ†’ pH โ‰ฅ 7,30 

  • DEFINITIONS โž 

                -    sev_MeAc = pH โ‰ค 7,20


10. RESULTS.

       a. 67yo โž– 59% โ™‚๏ธŽ

       b. 62% ๐Ÿ…ธ

       c. MM90 (p = 0.91)

             i.     62,1% โ†’ ๐Ÿ…ธ  

             ii.    61,7% โ†’ ๐Ÿ…ฒ

       d. acMM 28 & 180 โ†’ NO DIFF

       e. RRT (-23.1 to -7.8)
                    1. 35% โ†’ ๐Ÿ…ธ
                    2. 50% โ†’ ๐Ÿ…ฒ

       e. Others โ†’ NO DIFF

11. SOURCE:



2022 CC - Neostigmine for intraโ€‘abdominal hypertension in acute pancreatitis (he) [RCT]

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (AAQC)


Glossary: ACS = acute compartment syndrome, ADM = admission, AP = acute pancreatitis, CT = computed tomography, DIS = discharge, DYS = dysfunction, FLU = fluid balance, HD = hemodynamic, IAH = intra-abdominal hypertension, ITW = interview, NG = nasogastric, NJ = nasojejunal tube, OD = organ dysfunction, OF = organ failure, PCD = percutaneous catheter drainage, SAP = severe acute pancreatitis, sc = single center, Sx = surgery, UTI = urinary tract infection, WSACS = World Society for Abdominal Compartment Syndrome, ๐—ก๐—ข ๐——๐—œ๐—™๐—™ = no difference


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2022, CC, CH ๐Ÿ‡จ๐Ÿ‡ณ (Nanchang) โž– sc_pg_sup_pII_RCT โž• 80 (40 x 40) โž• Sep 2015 - Aug 2017 โž– P I C O:

- ๐Ÿ…ฟ: adults: AP + IAH (18 - 70 yo)

- ๐Ÿ…ธ: neostigmina โ†’ 1mg every 12h, 8h or 6hโ€ฆ depending on response.

- ๐Ÿ…ฒ: onventional TTO f_7d

- ๐Ÿ…พ: 

             -     pOC = % โ†“IAP at 24h (efficacy)

             -     sOC = ๐Ÿ’ฉ โ†‘ stool volume, ACS, new-onset ACS, โ†˜๏ธ IAH, new OD, MOD, MM, ๐Ÿซ respiratory OF, ๐Ÿซ€ circulatory OF, โ™พ๏ธ renal OF, ๐Ÿฅฃ timing of EN, ๐Ÿฉธ IA bleeding, ๐Ÿซƒ๐Ÿฝ enterocutaneous/enteric fistula, and ร†.


3. EVIDENCE

a. IAH in AP โ†” ORGAN DYS
b. SAP โ†” โ†‘ MM

       c. IAH = IAP โ‰ฅ12 mmHg (WSACS)

       d. Prospective โ–ถ๏ธŽ 37% MM โ†’ AP + IAH (17% of IAH in AP)

       e. Inflammatory state:

           i.     edema

           ii.    fluids collections

           iii.   ascites

           iv.   gut injury โ†’ PARALYTIC ILEUS

           v.    gastric dilatation 
       f. When IAP >20mmHg โ†’ ACS โž• OD

      g. Descompression โ†’ morbidity 

            i.   โˆ‘ non-operative are preferred:

                    1.     NG decompression

                    2.     promotility agents

                    3.     PCD

       h. Neostigmine:

             i.     anti-cholinesterase

             ii.    โ†—๏ธ peristaltis

             iii.   promotes passage of FLATUS + defecation 

             iv.   colonic decompression

             v.    WSACS โ†’ ๐Ÿ…ธ as TTO for colonic ileus IF no response to simple measures. 

        i. Colonic ileus CONFIRMATION (difficult to perfom in OD โŒ„ HD instability):

              i.    X-ray in standing position
              ii.   CT
        j. IF conventional TTO fail โžฉ think of paralytic ileus โ†’ NEOSTIGMINE could help.


4. METHODS.

  • ๐—œ๐—ก โž      

            - IAH within 2 w of AP onset โ†’ conventional TTO f_24h

            - IAP โ‰ฅ12 mmHg

  • ๐—˜๐—ซ โž      

             - H laparotomy

             - IA bleeding

             - contraindication neostigmin

                     - ๐Ÿซ€ angina,

                     - MI,
                     - VT,
                     - bradycardia,
                     - acute circulatory failure;
                     - ๐Ÿง  epilepsy;
                     - ๐Ÿซ bronchial asthma;
                     - ๐Ÿซƒ๐Ÿฝ mechanical intestinal obstruction,
                     - intestinal fistula;
                     - hyperthyroidism;
                     - ๐Ÿ“ˆ serious

                     - intestinal fistula   

                     - allergy to neostigmine.

             - UTI โŒ„ bladder Sx

             - Pregnancy & lactation

Friday, July 10, 2026 at 18:00:20 in BE

EQO, OWGG, YAPG, SLDC, HIBN, AAQC,


  • RANDOM โž  1:1
  • INTERV โž 

                -  NO DEFECATION

                       -  initially โ†’ every 12h

                       -  a_12h โ†’ every 8h

                       -  a_24h โ†’ every 6h

                -  STOP ๐Ÿ…ธ 

                       - IAP < 12mmHg

                       - IF not โ†“ โžฉ for 7d

                - EN

                       - IAP <15mmHg โ†’ NJ

                       - started 20mL/h โ†’ โ†‘ 15mL x8h
                       - goal 25-35 Kcal/Kg/d โ†’ depending on px TOLERANCE

                - PN

                        - โ‰ฅ15mmHg

                - SX decompression multidisciplinary seminar

                       - IAP > 25mmHg โŒ„ 

                       - OD + fulminant ACS

                - ฦ’-up

                       - 1, 3, 6m af_DIS

                       - ITW โŒ„ telephone

                      

DEFINITIONS โž 

                -   Conventional TTO (for 24h)

                        - sedations + analgesia

                        - NG decompression

                        - glycerin enema

                        - negative fluid balance

                        - PCD for ascitis

                 - Concomitant TTO (intervention + ฦ’-up)

                        - NG ยฑ rectal tube

                        - paraffin oil + liquid soaked + traditional Chinese medicine

                        - glycerin enema

                        - PCD for ascitis

                        - ๐Ÿ’‰ albumin, diuretics, RRT โ†’ for fluid overload

                        - sedation + analgesia IF agitation + asynchrony

5. RESULTS.

       a. Baseline โ†’ ๐—ก๐—ข ๐——๐—œ๐—™๐—™

       b. Rate of โ†“ IAP (p = 0.017)

             i.     ๐Ÿ…ธ faster โžฉ -18,7%

             ii.    ๐Ÿ…ฒ โžฉ -5,4%

       c. Subgroup IAP โ‰ฅ15mmHg (p = 0.018)F
             i.     ๐Ÿ…ธ more pronounced
             ii.    ๐Ÿ…ฒ

       d. Per-protocol ๐Ÿค“ โ†’ CONFIRMED (p=0.03)

       e. Stool volume d_7d (p<0.05)

             i.     ๐Ÿ…ธ consistently higher

             ii.    ๐Ÿ…ฒ 

       f. Other sOC โ†’ ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

6. RATIONALE.

โณ TIME MANAGEMENT.
02:31:08

Round: 11 00:49:92 Comment
Round: 10 39:48:99 RECAP
Round: 9 01:04:09 Article
Round: 8 12:48:22 Interpretation
Round: 7 03:34:56 Introduction
Round: 6 18:13:34 RECAP
Round: 5 01:10:05 Comments
Round: 4 01:57:91 Interpretation
Round: 3 02:50:68 Reading + notes
Round: 2 01:34:47 ART proposed
Round: 1 04:11:28 Past JC

June, 2026



2026 LANCET - EMPHASIS, efficacy and safety of minocycline in pxs w_ acute ischaemic Sโ€  (Lu) [RCT].pdf

Codified by YAPG


Glossary: GUSTO-PAO-CA = Global Utilisation of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries, h_ = haemorrhagic, i_ = ischaemic, LOC = level of consciousness, mRS = modified Rankin Scale, OR = odds ratio, QOL = quality of life, TTO = treatment


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, LANCET, CH ๐Ÿ‡จ๐Ÿ‡ณ โž– mc_db_pla_RCT โž• 1724 (862 ๐Ÿ†š 862) โž• May 2023 - May 2024 (1y) โž– P I C O:

- ๐Ÿ…ฟ: adults, a_iSโ€  โคน72h

- ๐Ÿ…ธ: minocycline

- ๐Ÿ…ฒ: placebo

- ๐Ÿ…พ: pOC = excellent functional OC โ†’ mRS 0-1 

       - sOC =

             -     90d mRS โ†’ ordinal shift ๐Ÿค“

             -     24h + 6d change NIHSS ๐Ÿ†š baseline
             -     6d change hs-CRP ๐Ÿ†š baseline
             -     24h + 6d early ๐Ÿง  deterioration 
             -     90d new Sโ€  (i_ + h_)
             -     90d new i_Sโ€ 
             -     90d composite: Sโ€  + MI + v_MM
             -     90d QOL โ†’ EQ-5D

  • pos-hoc EFFICACY OC:

            -     funcional independence โ†’ mRS โ‰ค2

     -      independent ambulation โ†’ mRS โ‰ค3

  • Safety OC:

            -     24h + 6d icHH (at least 1) โ†’ Heidelberg Bleeding Classification
            -      6d ATB-associated โ†’ diarrhoea + enteritis + constipation 

            -      90d any HH โ†’ GUST-PAO-CA
            -      90d v_MM
            -      90d ac_MM
            -      90d ร† reported by investigator 

3. EVIDENCE

a. Minocycline โ†’

           i.     muti-target anti-neuroinflammatory

           ii.    Potential benefits for i_Sโ€  โ†’ preclinical + small-scale clinical studies

          

Friday, July 17, 2026 at 18:30:47

EQO, LCO, LPM, YAPG, SLDC, BAR, HIBN, AAQC,


4. DEFINITIONS

       a. Dose = 200mg + 100mg every 12h f_4d


5. METHODS.

  • ๐—œ๐—ก โž   

              - NIHSS 4-25
              - LOC (subscale 1a) โ‰ค1

  • ๐—˜๐—ซ โž 
  • RANDOM โž 

             - 1:1 + routine TTO
             - fixed block size of 4 โ†’ computer-generated

  • INTERV โž 

6. RESULTS.
       a. 65yo โค 67% โ™‚๏ธŽ 

       b. Baseline NIHSS = 5

       c. Withdrew consent (4) + lost ฦ’-up (19)

       d. Excellent functional OC โ†’ mRS 0-1 (p = 0.0061)

             i.     ๐Ÿ…ธ 53%

             ii.    ๐Ÿ…ฒ 47%

       e. 90d mRS โ†’ ordinal shift ๐Ÿค“ (p = 0,018)
             i.     ๐Ÿ…ธ โœ”๏ธŽ โ†’ OR 1,19
             ii.    ๐Ÿ…ฒ โœ–๏ธŽ

       f. 24h + 6d icHH (at least 1) โ†’ Heidelberg Bleeding Classification

             i.     ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

       g. Other safety OC

             i.     ๐—ก๐—ข ๐——๐—œ๐—™๐—™

6. RATIONALE.



















8. SOURCE: Lu Y, Guan L, Wu J, et al. Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial. Lancet. 2026;407(10529):679-688. doi:10.1016/S0140-6736(25)01862-8

โณ TIME MANAGEMENT.
01:49:06

Round: 6 02:02:35 Comments
Round: 5 56:51:76 RECAP
Round: 4 20:24:33 Interpretation
Round: 3 05:39:79 Reading + notes (abstract)
Round: 2 01:18:70 ART selection
Round: 1 22:49:77 Past JC



2022 CCM - Therapeutic Hyperthermia Is Associated w_Improved in Afebrile CIpxs w_ Sโ€ข (Drewry) [RCT].pdf

Codified by YAPG


Glossary: CA = cancer, DIS = disease, โ†“imm = immunosuppression, HLA = human leukocyte antigen, IFN = interferon gamma, L = lymphocytes, LPS = lipopolysaccharides, NK = natural killer, po_ = postoperative, r = risk, Sโ€ข = sepsis, sc = single center, โคน = prior to


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2022, CCM, Washington ๐Ÿ‡บ๐Ÿ‡ธ  โž– sc_pros_ol_RCT โž• 1200bed โ†’ 56 pxs โž• Mar 2016 - Apr 2019 (3y)  โž– P I C O:

- ๐Ÿ…ฟ: MV_Sโ€ข_adults

- ๐Ÿ…ธ: โ†‘ Tยบ

- ๐Ÿ…ฒ: standard Tยบ

- ๐Ÿ…พ: 

             -     pOC = monocyte HLA-DR expression

             -     sOC = CD3/CD28 induced IFN-โˆ‚ production โž• MM โž• fd_H+28
             -     oth_OC = feasibility โž• safety

3. EVIDENCE. 

       a. โ†‘Tยบ โ†—๏ธ immune function

       b. Fever โ†’ 
             i.    fewer than half in Sโ€ข
             ii.   may be ADAPTIVE RESPONSE to INF โ†’ โ†—๏ธ  SS
       c.  Afebrile pxs โ†’ 2x โ†‘MM โž• more likely to INF
       d. Animals + in vitro โ–ถ๏ธŽ โ†‘Tยบ โ†’ โ†‘:

             i.    Ab production

             ii.   T-cell โŠ• 

             iii.   macrophage function

             iv.   heat shock protein response
        e. SEPSIS โ†’ mechanisms PRO + ANTI-inflammatory โžฉ ๐Ÿšจ prolonged โ†“imm

        f. Biomarkers โ†” โ†“imm

             i.    โ†“ HLA-DR
             ii.   โ†“ LPS TNF-โ™พ๏ธ 
             iii.  โ†“ anti-CD3/CD28-IFN-โˆ‚

             iv.  โ†“ L

        g. โ†“imm persistent (compared to INTACT immunity):
             i.    โ†‘ MM

             ii.   โ†‘ INF

        h. โ†‘ Tยบ:

             i.    immunomodulation in CA

             ii.   โ†—๏ธ function: 

                      1. NK
                      2. dentritic cells
                      3. T cells
             iii.   perioperative warming 

                      1. โ†“ po_INF

4. DEFINITIONS
       a. Severe Sโ€ข (inicial 2001 consensus) ๐Ÿ†š sepsis 3 (post-hoc review)

5. METHODS.

  •  ๐—œ๐—ก โž 

             - ๐Ÿชฒ Sโ€ข in 48h
             - ๐Ÿซ anticipated MV >48h
             -  ๐Ÿ’‰ sedation w_RASS <0             - ๐ŸŒก๏ธ MAX 38.3ยบC within 24h โคน 

Friday, July 24, 2026 at 18:00:13

EQO, LCO, RMCF, YAPG, HIBN, AAQC,


  • ๐—˜๐—ซ โž 

            - immunologic DIS

            - immune-suppressing MEDs 6m

            - corticosterids >300 mg/d hydrocortisone or โ‰ˆ
            - Hep C โŒ„ C
            - any condition sensitive to โ†‘Tยบ (๐Ÿง  injury, etc.)
            - pregnancy

            - comfort TTO

            - contraindication of warming
            - other enrollment

  • RANDOM โž  1:1 โž• computer โž• block 2,4,6
  • INTERV โž  forced-air warming blanket 48h โ†’ goal 1,5ยบC โ†‘ the lowest Tยบ (documented)

6. RESULTS.
       a. HLA-DR expression (p=0.396)

             i.     ๐Ÿ…ธ 692

             ii.    ๐Ÿ…ฒ 2002

             iii.    โˆ‘ ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

       b. IFN-โˆ‚ production (p=0.678)
             i.     ๐Ÿ…ธ 31
             ii.    ๐Ÿ…ฒ 69

             iii.   โˆ‘ ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

       c. MM28 (95%CI -48 to -2)

             i.     ๐Ÿ…ธ 18

             ii.    ๐Ÿ…ฒ 43

             iii.   absolute r_โ†“ 25%

       d. fd_H+28 (95%CI 0-11,6)

             i.     ๐Ÿ…ธ 13.1

             ii.    ๐Ÿ…ฒ 0

             iii.   DIFF 2,6

7. RATIONALE.































8. SOURCE: Drewry AM, Mohr NM, Ablordeppey EA, et al. Therapeutic Hyperthermia Is Associated With Improved Survival in Afebrile Critically Ill Patients With Sepsis: A Pilot Randomized Trial. Crit Care Med. 2022;50(6):924-934. doi:10.1097/CCM.0000000000005470

โณ TIME MANAGEMENT.
01:48:38

Round: 10 04:12:00 Comments
Round: 9 35:16:62 Methods
Round: 8 15:18:52 RECAP
Round: 7 11:12:90 Interpretation
Round: 6 02:57:83 Reading + notes (Intro)
Round: 5 15:04:70 RECAP
Round: 4 10:04:06 Interpretation
Round: 3 03:19:78 Reading + notes (abstract)Round: 2 00:43:96 ART selectionRound: 1 10:27:78 Past JC



2026 JAMA - The Sodium Paradox in Decompensated HF (Biegus) [vp].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (YAPG)


Glossary: โ˜… = recommendation(s), ๐Ÿ’จ = flow = perfusion, ร† = adverse effects, ESC-HF-A = European Society of Cardiology Heart Failure Association, HF = Heart FailurE, HTA = hypertension, HTS = hypertonic saline, MECHS = mechanisms, pPHY = pathophysiology, RAAS = renin-angiotensin-aldosterone system, supp = supplementation, UO = urine output, โˆ‘ = consequently


1. Maladaptive handling โ†’ CENTRAL โ†’ pPHY of HF


2. 2 key OBS:

       a. HOMEOSTASIS

              i.    impaired โ†’ โ†‘ accumulation

              ii.   pxs cannot excrete it adequately

       b. EXCESS

              i.    edema + ๐Ÿซ congestion

              ii.   โ€œexperimental exposureโ€ NaCl โ†’ Na retention + congestion

       c. โˆ‘ REASONING 

             i. โ Na restriction should PREVENT further accumulation of Na + H2O โ†’ โ†“ congestion โ–ถ๏ธŽ OFTEN FAILS TO DO SO

3. Na needed to โ†“ โ€œNa + H2Oโ€

       a. Considerations that contradicts (traditional paradigm):
             i.    Natriuresis:

                      1. positive relation w_UO

                      2. Na = critical fator in effective urine โ—๏ธ 
             ii.   Loop diuretics

                      1. act through โ†’ Na dependen MECHS

             iii.  Regulators (Na + Cl)

                      1. intravascular tonicity

                      2. RAAS

                      3. diuresis

       b.  pPHY considerations:

             i.    Na helps PRESERVE โ™พ๏ธ function, through MODULATION:

                      1. RAAS

                      2. intraglomerular HTA

                      3. glomerular ๐Ÿ’จ 

             ii.   All the previous remain THEORETICAL 

        c. Na AVAILABITY โž• PROPER HANDLING

             i.    โžฉ effective DECONGESTION.
             ii.   challenges CONVENTIONAL WISDOM
             iii.  demands REEXAMINATION in light of emerging clinical data.

         

Friday, August 21, 2026 at 19:18:09 CEST

BAR, SLMG, HIBN, AAQC,

4. BENEFIT โ†’ Na+Cl supplemenation

       a. NaCl supp โ†’ decongestive benefits in decompensated HF

      b. Relaxation of Na restriction โžฉ โ˜… ESC-HF-A document (Eur J Heart Fail. 2024)

      c. Previous research โ–ถ๏ธŽ limit Na intake (pxs + healthy):

              i.     โ†“ natriuresis of furosemide

              ii.    โ†‘ diuretic tolerance

       d. Animal models (shock) โ–ถ๏ธŽ HTS

              i.     โ†‘ central hemodynamic

              ii.    โ†‘ visceral ๐Ÿ’จ 

              iii.   โ†‘ UO

        e. Salt supp โžฉ โ†“ neurohormonal drive (core MECH in pPHY HF)

         f. โˆ‘ โžฉ sound good to USE NaCl supp

         g. Real-world data โ–ถ๏ธŽ HTS in diuretic-refractory HF:

              i.    โ†‘ diuretic effciency

              ii.    โ†‘ weigh loss
              iii.    โ†—๏ธ clinical + metabolic

              iv.    wo_ร†

          h. MA of RCTs โ–ถ๏ธŽ benefit w_ โ€œHTS+furoโ€ ๐Ÿ†š โ€furo aloneโ€:

              i.     diuresis

              ii.    natriuresis

              iii.   โ†‘ clinical end points

           i. TARGET-1 โž• TARGET-2 โ–ถ๏ธŽ 

              i.     Reprieve System

                          1. automated fluid mm system 

                          2. monitors UO 
                          3. returns a matched volume of 0.9% NaCl

                          4. maintains a set fluid balance

              ii.     ๐Ÿ…ฟ decompensated HF pxs

              iii.    ๐Ÿ…ธ Reprieve System therapy + diuretics

              iv.    ยฎ โ†‘ UO (6L/d) d_infusion ๐Ÿ†š 2L/day (day before)

              v.     ยฎ โ†‘ UO (2L/d) a_infusion 

              vi.    โˆ‘1 โ†ช๏ธŽ ๐Ÿ…ฟ could 

                          1. EXCRETE Na+H2O โ contradictory to traditional dogma

                          2. maintained a (-) balance Na-H2O โdespite or perhaps in response to supp

              vii.   โˆ‘2 โ†ช๏ธŽ ๐Ÿ…ฟ w_NaCl infusion could more effectively:

6. RESULTS.

                          1. EXCRETE Na

                          2. EXCRETE volume

               viii. Set balance = 100mL/h net negative
       j.

 7. SOURCE:

โณ TIME MANAGEMENT.
01:28:09

Round: 8 01:05:47 Comments
Round: 7 22:12:32 RECAP
Round: 6 12:34:44 Interpretation 2
Round: 5 14:38:18 RECAP 1
Round: 4 12:28:92 Interpretation
Round: 3 09:47:87 Reading + notes
Round: 2 08:15:87 ART selectionRound: 1 07:06:73 Past JC

July, 2026



2024 JACP - Neuroprognostication After Cardiac Arrest (Kromm) [CP].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (MASP)


Glossary: af_ = after, CA = cardiac arrest, DX = diagnostic, diagnosis, DYSF = dysfunction, HIBI = hypoxic-ischemic brain injury, ischHepat = ischemic hepatitis, neuroPROG = neuroprognostication, TTO = treatment, WLST = withdrawal of life-sustaining therapies


1. UNCERTAINTY โžฉ coma af_CA

      a. DX

      b. TTO

      c. despite โ†’ advances in TECH + RESUS CARE

      d. How best to prognosticate?


2. GL โ–ถ๏ธŽ variability in CLINICAL PRACTICE

3. Clinical case โ†’ PRINCIPLES evaluated + APPROACH to neuroPROG

       a. Clinical exam

       b. Neuroimaging

       c. Neurophysiology

       d. Multimodal approach

       e. Multidisciplinary team
4. INCIDENCE

       a. OHCA 47,3 per 100k person/y

       b. IHCA 1,8 per 1k admissions/y

5. COMATOSE postCA โžฉ 80% โ†’ HIBI


         

Friday, August 28, 2026 at 18:05:08 CEST

BAR, SLMG, HIBN, AAQC,

6. DEATH:

       a. small proportion โ†’ HD instability + MOD

       b. frequent case โ†’ WLST

7. Best practice to AVOID:

       a. inappropriate WLST

       b. premature WLST

       c. harmful invDev

8. CLINICAL CASE

       a. 56yo โ™‚๏ธŽ

       b. Unresponsive (drug paraphernalia)

       c. Unwitnessed, asystolic OHCA

       d. 10min CPR

       e. 2x EPI

        f. ROSC

        g. H+ โ†’ GCS 3 + โ€œfixed & dilatedโ€ pupils.

        h. CAUSE

             i.    drugs overdoseโ€ฆ? โ†’ opioids + BZD + metamphetamines urine
             ii.   ECG + ECHO + RX โ†’ โŠ–
             iii.  CT โ†’ โŠ–

             iv.   LAB โ†’ AKI + ischHepat (mild synthetic DYSF)

             v.    ICU โ†’ GCS 4 (motor 2โ€ฆ 1, 1) + jerking movements (face + limbs)

         i. TTO         

              i.     levetiracetam
         j.  EEG

              i.     generalized slowing + suppression

              ii.    no epileptiform discharge or seizures

 7. SOURCE: Kumar P, Kaur K. Neuroprognostication after cardiac arrest: Updated insights from the 2025 ERC-ESICM guidelines. J Anaesthesiol Clin Pharmacol. 2026;42(2):171-174. doi:10.4103/joacp.joacp_695_25

โณ TIME MANAGEMENT.
01:28:09

Round: 8 01:05:47 Comments
Round: 7 22:12:32 RECAP
Round: 6 12:34:44 Interpretation 2
Round: 5 14:38:18 RECAP 1
Round: 4 12:28:92 Interpretation
Round: 3 09:47:87 Reading + notes
Round: 2 08:15:87 ART selectionRound: 1 07:06:73 Past JC

September, 2026

Friday, September 18, 2026 at 18:31:25 CEST

EQO, LCO, MJLD, MLHG, KYEC, AHO, RCH, BAR, HIBN, AAQC,



2026 JACC - PE GL | Guideline for the Evaluation + mm of APE in Adults (Creager) [GL].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (AAQC)


Glossary: advOC = adverse outcomes, AHRQ = Agency for Healthcare Research and Quality, aPE = acute pulmonary embolism, BLEED = bleeding, CLIsev = clinical severity score, CTEPD = chronic thromboembolic pulmonary disease, DaBa = database, hr = high risk, LMWH = low-molecular-weight heparin, lr = low risk, MECH = mechanical, MSSGS = messages, PERTS = PE response teams, SX = surgical, SYS = systemic, UFH = unfractionated heparin, VTE = venous thromboembolism

>rf = major risk factors


<rf = minor risk factors


per_rf = persisten risk factors



1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. 2026, JACC, USA ๐Ÿ‡บ๐Ÿ‡ธ โž– GL โž• NA โž• Feb-Oct 2024 (Apr 2025) โž– P I C O:

  • ๐Ÿ…ฟ: adults โ‰ฅ18yo
  • ๐Ÿ…ธ: aPE
  • ๐Ÿ…ฒ: NA
  • ๐Ÿ…พ: classification โž• prognosis โž• therapeutic

3. METHODS.

       a. Is a de novo GL

       b. MEDLINE (PubMed), EMBASE, Cochrane, AHRQ, othe DaBa

       c. Structure โ†’ OC assessment, CLI DX, CV testing, mm a_ + early post-acute phases.


4. TAKE-HOME MSSGS

       a. CLASSIFICATION

            i.    5 categories โ†’ A-E

            ii.   Subcategories โ†’ lr-hr advOC

       b. WHEN to DIS home โ“ 

            i.    asymptomatic = Cat A

       c. When H+ DIS โ“ 

            i.    Symptomatic, but 

            ii.   CLIsev โ†“ = Cat B

       d. WHEN to HOSPITALIZE โ“

            i.    Cat C, D, E โžฉ should be hospitalized

       e. THERAPIES

           i.     E1 โ†’ are reasonable (MODERATE class)

           ii.    D1-2 โ†’ can be considered (MODERATE class)

           iii.   Which?

                     1. SYS thrombolysis
                     2. catheter-based thrombolysis

                     3. MECH thrombectomy

                     4. SX embolectomy

        f. PERTs โ†’ โ†—๏ธ timeliness of care

       g. ๐Ÿ’‰ AC

            i.    LMWH โœ”๏ธŽ ๐Ÿ†š UFH โœ–๏ธŽ 

       h. ORAL AC

            i.    DOACs โœ”๏ธŽ ๐Ÿ†š VKAs โœ–๏ธŽ 

            ii.   Unless contraindicated

            iii.   โ†“ VTE โž• โ†“ BLEED

        i. 1st aPE โžฉ AC 3-6m โ†’ EXTENDED TTO:

            i.    wo_>rf

            ii.    w_per_rf 

        j. โคน aPE โžฉ every visit for 1y (minimum):

            i.     โ“ symptoms 

            ii.    โ“ functional limitations

            iii.    โ†ช๏ธŽ to screen for CTEPD + dyspnea + functional limitation


         

5. DEFINITIONS

       a. HA/ACC Acute PE Clinical Categories

    

โณ TIME MANAGEMENT.
02:03:24

Round: 10 01:27:20 Comments
Round: 9 13:42:47 Interpretation
Round: 8 16:29:77 Clinical decision rules
Round: 7 28:11:33 RECAP
Round: 6 31:21:48 Interpretation
Round: 5 03:11:91 Take-home mssgs
Round: 4 03:21:63 Interpretation
Round: 3 02:53:30 Reading + notes
Round: 2 04:23:04 CommentsRound: 1 18:22:13 Past JC

       b. CLIsev

    

       c. rf_VTE